What are you looking for? Write the name, title or any keyword related to what you are looking for and select which content category it belongs to. Search Fulltext search Activities Professionals Research groups News - Any - Activities Vall d'Hebron Talks by VHIR 'Epigenetics and Inflammation: Basic Mechanisms and Clinical Implications for Sepsis' Speaker: Dr. Esteban Ballestar, Group Leader in Epigenetics and Immunity at IJC, Barcelona. Epigenetic modifications have key implications in relation to gene expression and associate with cell function. The patterns of epigenetic modification are highly sensitive to extracellular signa News A new clinical algorithm increases the diagnosis rate of rare diseases The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools. Activities Métodos diagnósticos para la evaluación de las alteraciones de la dinámica de LCR y su aplicación en la hidrocefalia - Segunda Edición Más información: https://aula.vallhebron.com/aula/?go=info_cursos&curso=560 Aula Vall d’Hebron News Vall d'Hebron has participated in one of the clinical trials that have enabled the approval of the first specific pill for postpartum depression in the United States The new drug improves core symptoms of depression in just three days News The EU-PEARL consortium, led by Vall d'Hebron, presents a European framework for collaborative clinical trial platforms This new method improves and streamlines drug development processes News Vall d'Hebron leads an international phase III clinical trial demonstrating the efficacy of atogepant, an oral drug for the prevention of chronic migraine The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication. News The study of the expression of certain genes in blood samples helps to predict the risk of ADHD Complemented with the analysis of genetic variants, the work led by Vall d'Hebron establishes the basis for using gene expression as a potential biomarker of risk of developing the disorder. News The Lancet Haematology highlights the actions of the ERN-EuroBloodNet to improve sickle cell disease research This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care. News Smoking is one of the causes of cluster headache, an international genetic study with the participation of Vall d'Hebron shows The results show that tobacco affects the expression of some genes related to the development of this type of headache. News Before a spinal operation, greater risks can be predicted, thanks to a Vall d'Hebron study with the UPF and Hospital del Mar The work improves accuracy in predicting complications at the boundary between the instrumented spine area and the area that is left free when spinal deformity corrective surgery is performed. News Vall d'Hebron Research Institute PhD Programme 2023 Open Call The Vall d’Hebron Research Institute makes its own and open call for a doctoral fellowship programme devoted to attracting early-stage researchers with a special interest in biomedical research. News VHIR will be a model and strategic partner to promote clinical and translational research at Instituto de Medicina Molecular Joao Lobo Antunes (iMM) The IMM-CARE project has been presented at an institutional event in Lisbon. Activities Defensa de tesi 'Hepatoencefalopatia deguda a mutacions en GFM1: obtenció d’un model de ratolí modificat genèticament i estudi preclínic de teràpia gènica amb vectors adenoassociats' Doctorand: Miguel Molina Berenguer, grup de Recerca de Patologia neuromuscular i mitocondrial (VHIR) Directors: Dr. Javier Torres Torronteras i Dr. Ramon Martí Seves News Vall d'Hebron shows that starting medication in patients with first symptoms of multiple sclerosis reduces long-term disability The results show for the first time that patients who start treatment less than six months after having the first symptoms of the disease have a slower progression and less disability than when therapy is started more than 16 months later. News Vall d'Hebron proves the safety of the use of a virus for the treatment of pediatric tumors The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse. News We present the VHIR Annual Report 2022 It highlights the scientific and institutional results of the center during 2022. News Vall d'Hebron points to the usefulness of smartwatches as a complementary tool to medical care to detect arrhythmias after stroke Smartwatches are a practical, low-cost, noninvasive method that helps in the early detection of atrial fibrillations in some patients, which increase the risk of recurrent stroke. News Dr. Sara Marsal wins a trifermed award for Social Impact in Healthcare The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field. News SYNLAB and Vall d'Hebron sign collaboration agreement to promote medical research It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy. Activities Clone of Vall d'Hebron Talks 'Prevenció combinada del VIH: PrEP, PEP i TasP' Ponents: Dr. Vicente Descalzo, facultatiu del Servei d'Infeccioses de l'Hospital Universitari Vall d'Hebron i investigador del Grup de Recerca de Malalties Infeccioses del Vall d'Hebron Institut de Recerca (VHIR) CV: metge internista, adjunt a la unitat ITS-VIH Drassanes Vall Pagination First page « Previous page ‹ … Page 25 Page 26 Current page 27 Page 28 Page 29 … Next page › Last page »
